K562-IMA[r] - CELLS

Title

K562-IMA[r] - CELLS

Cat. No.: 
10013C
Price $995.00
Unit: 
1 million cells per cell line
Description: 

K562-IMA[r] viable cells.

K562-IMA[r] cells are 145-fold more resistant to inhibition by IMATINIB than parental K562 cells: IMATINIB IC50s for K562-IMA[r] and parental K562 cells are 14.7 µM vs 101 nM, respectively (MTT assay). K562-IMA[r] cells were established following 8 months of continuous in vitro exposure of parental K562 cells to IMATINIB.

K562-IMA[r] cells are available through a licensing agreement with ChemoScreen. The listed price is for a two-year license.

Cell Line: K562 is an erythroleukemia cell line established from a 53 year old female with CML in blast crisis (Lozzio and Lozzio, 1975). The cell line bears the Philadelphia chromosome and associated BCR/ABL1 chimeric protein.

PParent phenotype: CD1-, CD2-, CD3-, CD4-, CD5-, CD7-, CD8-, CD9+, CD11b(+), CD13+, CD14-, CD15+ CD28-, CD10-, CD19-, CD20-, CD21-, CD22-, CD25, CD33+, CD34-, CD36-, CD38-, CD41+, CD42b-, CD44+, CD45+, CD56-, CD57-, CD61(+), CD65+, CD71+, CD80+, CD86-, CD117(+), CD122+, CD132+, CD235a/GlyA+, PPO-, vWF-, HLA-DR-, TdT-, EPO-R+, TCRα/β-, TCRγ/δ- (Drexler and Wehler).

Parent genotype: (COSMIC database, October 2014): Mutated genes: 197 point mutations, inserts and deletions reported. Key lesions are the BCR/ABL1 fusion and CDK2NA mutation (c.151_457del307).

Compound: Inhibits the tyrosine kinase domains of multiple tyrosine kinases including ABL1, BCR/ABL1, KIT, and PDGF-R.